peripheral arterial disease/protease

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

10 rezultatima

Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

EXISTING KNOWLEDGE AND MAIN ASSUMPTIONS OF THE PROJECT. Atherosclerosis is the most common cause of peripheral artery disease (PAD). The first symptom of PAD is intermittent claudication (IC), which is characterized by the occurrence of pain, cramps, numbness, and discomfort in the lower limb

Platelet PAR-1 Activation in Health and Diabetes

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Atazanavir and Endothelial Function in Older HIV Patients

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

The mortality induced by HIV has dropped significantly due to effective antiretroviral therapy. Epidemiological data suggest a less than 5% 10-year mortality for patients treated with HAART. As a result of the reduction in early AIDS-related deaths, HIV has become a chronic disease manifesting the

Vorapaxar and Lower Extremity Bypass Grafts

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Peripheral artery disease (PAD) is characterized by atherosclerotic occlusive disease of the lower extremities. More than 8 million Americans and 200 million people globally have PAD. Recent data reveal a prevalence of 15% in the MEDICARE population. In populations at risk, patients with a history

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI) or peripheral arterial disease (PAD). However,

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI). The novel P2Y12 receptor inhibitors prasugrel and ticagrelor are characterized

IPHAAB-study Influence of Physical Activity on Atherosclerosis Biomarkers

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

According to Statistik Austria, cardiovascular disease (CVD) is the most common reason for death in Austria in total population. In 2011, 42,3 % of all deaths were due to CVD (ICD-10 I00-I99). In People aged 45-64 years, CVD is, beyond cancer, the second most common cause of death. According to the

Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Why is this clinical problem important? Peripheral Arterial Disease (PAD) is a major health problem in Australia, with a prevalence of 15% in males aged over 65 years. The direct health care cost of PAD in Australia was $180m in 1994, of which 78% was associated with hospitalisations. PAD is also a

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Study Endpoints: Primary Endpoint: • The primary endpoint of this study is the change in the kinetics of tissue hemoglobin oxygen desaturation (expressed as time constants) following the onset of exercise. Secondary endpoints of this study include percent and absolute change in: - Peak oxygen

Effect of Atazanavir on Endothelial Function in HIV-Infected Patients

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Indication: Dyslipidemia Type II in HIV-Infected Patients Primary Objectives: Change of flow-mediated dilation in the forearm after 6 months using the protease inhibitor atazanavir in a potent antiviral therapy combination compared with a combination including current proteinase inhibitor. Secondary

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima